| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| Bloomberg ticker | RVTY US |
| ISIN code | US7140461093 |
| Industry group | Healthcare |
| Aligned with SDGs |
Revvity is an American healthcare equipment and technology company that serves the diagnostics and life sciences (drug discovery) markets worldwide. It operates through the segments Life Sciences (products and services for life sciences research) and Diagnostics (tools and applications for clinical customers in reproductive health, emerging market diagnostics and applied genomics markets). The company’s customers include academic and research organizations, biotechnology and pharmaceutical companies, doctors, government agencies, laboratories, private health care organisations, and public health authorities.
Investment rationale
Revvity contributes to advancing global health and wellbeing by enabling earlier detection, better diagnostics, and faster scientific breakthroughs. As the global market leader in life-saving screening tests for newborns and expectant mothers, the company empowers healthcare providers to identify and treat conditions such as pre-eclampsia and other congenital disorders at the earliest possible stages — helping give children a healthier start in life. Revvity differentiates itself through its comprehensive portfolio of diagnostic, imaging, and informatics solutions, which connect science and technology to improve outcomes across the healthcare continuum. By supporting researchers in accelerating the discovery-to-commercialisation process, Revvity helps bring better medicines to market faster. The company also extends its impact beyond innovation, contributing to stronger healthcare systems in developing regions through initiatives such as the donation of diagnostic kits and collaborative capacity-building efforts.
Alignment with Triodos Transitions:
In total 90% of the revenues of the company is aligned with the Wellbeing Transition. The contribution to the Wellbeing Transition comes from 90% of revenues related to the impact objective Health Care.